Organovo Holdings Inc. boosted its balance sheet by $40.5 million in a public offering to advance work on its 3D bioprinting technology, with aims of delivering to the market applications both for drug discovery and development and for regenerative medicine products. Read More
SHANGHAI – Still avoiding discussion of its failed bid for Onyx Pharmaceuticals Inc. in June, Amgen Inc. continues to implement an ambitious Asia expansion strategy when it announced the launch of a new collaboration with Japan's Teijin Pharma Ltd. to search for new therapies for autoimmune diseases. Read More
Zalicus Inc.'s shares gained ground the day after second-quarter earnings rolled out, as investors reawakened to the potential of Z160, the firm's Phase II oral, N-type calcium channel blocker for chronic pain. Read More
There is no doubt that senior executives of emerging biotechs spend much of their time on the trail of investment capital. The Coalition of Small Business Innovators (CSBI) would like to ease that burden. Read More
Transition Therapeutics Inc. will receive an investment of up to $21 million from certain shareholders purchasing 2.5 million units of the company's stock at $4.19 per share. The financing will support the company through completion of three Phase II studies. Read More
"We are used to thinking of depression as a mental illness, or those of us that are more biologically inclined, as a brain disorder," Owen Wolkowitz told his audience during a recent talk at the National Institutes of Health (NIH) on "Getting Old Before Our Time: Psychiatric Illnesses and Accelerated Cell Aging." Read More
• Thallion Pharmaceuticals Inc., of Dorval, Quebec, said the effective net cash in the amended agreement for its acquisition by Bellus Health Inc., of Laval, Quebec, equals at least $7.5 million, including proceeds from the exercise or cancellation of "in-the-money" options of approximately $500,000, resulting in at least $0.1765 per common share in cash to Thallion's shareholders. Read More
• Stemcells Inc., of Newark, Calif., presented data showing that two years after transplantation of its purified human neural stem cells into patients with Pelizaeus-Merzbacher disease (PMD), magnetic resonance imaging (MRI) suggested myelination was more pronounced than at one year post-transplantation. Read More
• Actavis Inc., of Parsippany, N.J., said Actavis Ltd., Bank of America N.A., as administrative agent, and a syndicate of banks participating as lenders have entered a new senior unsecured term loan credit and guaranty agreement, pursuant to which the lenders party to the agreement will provide loans, on the closing date of Actavis' proposed acquisition of Warner Chilcott plc, of Dublin, to certain entities of Warner Chilcott in an aggregate amount not to exceed $2 billion, comprising a $1 billion three-year tranche and a $1 billion, five-year tranche. Read More
